Patents by Inventor Ruth McAdam
Ruth McAdam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210017270Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: July 9, 2020Publication date: January 21, 2021Inventors: Gary Peter BEMBRIDGE, Chun-wa CHUNG, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
-
Patent number: 10808029Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: February 9, 2017Date of Patent: October 20, 2020Assignee: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
-
Publication number: 20180086835Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: November 21, 2017Publication date: March 29, 2018Inventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Patent number: 9850307Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: GrantFiled: September 2, 2015Date of Patent: December 26, 2017Assignee: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20170152312Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: February 9, 2017Publication date: June 1, 2017Inventors: Gary Peter BEMBRIDGE, Chun-wa Chung, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
-
Patent number: 9605063Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: November 13, 2014Date of Patent: March 28, 2017Assignee: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
-
Publication number: 20150361176Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: September 2, 2015Publication date: December 17, 2015Inventors: Andrew BEATON, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Patent number: 9150651Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: GrantFiled: January 4, 2012Date of Patent: October 6, 2015Assignee: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20150064201Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: November 13, 2014Publication date: March 5, 2015Inventors: GARY PETER BEMBRIDGE, CHUN-WA CHUNG, SUSANNAH KAREN FORD, IAN KIRBY, RUTH MCADAM, MARIA FEENEY
-
Patent number: 8916695Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: November 21, 2011Date of Patent: December 23, 2014Assignee: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
-
Publication number: 20130302335Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: January 4, 2012Publication date: November 14, 2013Applicant: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20130287781Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing such antibodies and the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.Type: ApplicationFiled: January 28, 2013Publication date: October 31, 2013Inventors: Stephanie Jane CLEGG, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabiner Kumar Prinjha
-
Publication number: 20130251724Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: November 21, 2011Publication date: September 26, 2013Applicant: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
-
Patent number: 8362208Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.Type: GrantFiled: December 14, 2006Date of Patent: January 29, 2013Assignee: Glaxo Group LimitedInventors: Stephanie Jane Clegg, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabinder Kumar Prinjha
-
Publication number: 20120128689Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).Type: ApplicationFiled: March 30, 2010Publication date: May 24, 2012Applicant: Glaxo Group LimitedInventors: Jane Elizabeth Clarkson, Ruth McAdam, Alan Peter Lewis
-
Publication number: 20110206686Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).Type: ApplicationFiled: October 3, 2008Publication date: August 25, 2011Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth Mcadam
-
Patent number: 7988964Abstract: The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.Type: GrantFiled: December 20, 2004Date of Patent: August 2, 2011Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Alexandre Eon-Duval, Robert Ian Grundy, Farhana Hussain, Ruth McAdam, Christopher Plumpton, Rabinder Kumar Prinjha, Paul Alexander Wilson
-
Publication number: 20100221260Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.Type: ApplicationFiled: December 14, 2006Publication date: September 2, 2010Inventors: Stephanie Jane Clegg, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabinder Kumar Prinjha
-
Publication number: 20090123479Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).Type: ApplicationFiled: October 3, 2008Publication date: May 14, 2009Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth McAdam
-
Publication number: 20070065430Abstract: The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.Type: ApplicationFiled: December 20, 2004Publication date: March 22, 2007Applicant: Glaxo Group LimitedInventors: Jonathan Ellis, Alexandre Eon-Duval, Robert Grundy, Farhana Hussain, Ruth McAdam, Christopher Plumpton, Rabinder Prinjha, Paul Wilson